Wells Fargo Maintains an 'Outperform' on Achillion Pharmaceuticals (ACHN); A Few Hiccups, But Expect Positive N-T Data
Tweet Send to a FriendGet Alerts ACHN Hot Sheet
Price: $7.64 -1.29%
Rating Summary:
14 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 21 | Down: 24 | New: 29
Rating Summary:
14 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 21 | Down: 24 | New: 29
Trade ACHN Now!
Wells Fargo maintains an 'Outperform' on Achillion Pharmaceuticals (NASDAQ: ACHN) price target range $11-13 from $14-16.
Analyst, Brian Abrahams, said, "We expect near-term data for '1625, '2684 and '3102 to confirm the promise of ACHN's HCV portfolio and drive potential upside...However, EASL also made apparent several potential negatives: the “sheen” on ‘1625’s previously-untarnished safety and efficacy profile having been lost a bit, the increasing reliance ACHN has on a preclinical asset (‘3102) for an in-house alloral combo, and the rapidly-moving developmental space theoretically narrowing where ‘1625 could fit strategically. We are reducing our valuation range and could see shares trade rangebound near-term; nonetheless, we remain positive on ACHN shares longer-term, as we believe the differentiating features of ‘1625 and the rest of ACHN’s portfolio could still make them coveted parts of future HCV regimens. Lowering 2013E EPS to -$0.52 from -$0.45."
For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.
Shares of Achillion Pharmaceuticals closed at $8.28 yesterday, with a 52 week range of $3.81-$12.95.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Brian Abrahams, said, "We expect near-term data for '1625, '2684 and '3102 to confirm the promise of ACHN's HCV portfolio and drive potential upside...However, EASL also made apparent several potential negatives: the “sheen” on ‘1625’s previously-untarnished safety and efficacy profile having been lost a bit, the increasing reliance ACHN has on a preclinical asset (‘3102) for an in-house alloral combo, and the rapidly-moving developmental space theoretically narrowing where ‘1625 could fit strategically. We are reducing our valuation range and could see shares trade rangebound near-term; nonetheless, we remain positive on ACHN shares longer-term, as we believe the differentiating features of ‘1625 and the rest of ACHN’s portfolio could still make them coveted parts of future HCV regimens. Lowering 2013E EPS to -$0.52 from -$0.45."
For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.
Shares of Achillion Pharmaceuticals closed at $8.28 yesterday, with a 52 week range of $3.81-$12.95.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Jefferies Lifts Numbers on Diana Shipping (DSX) Post Q1
- Notable HP (HPQ) Bear Speaks, Says 'Recovery Unsustainable'
- Deutsche Bank Raises PT on NetApp (NTAP) to $48
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change, FDARelated Entities
Wells Fargo
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
